Dr. Dorff on Incorporating mCRPC Prognostic Models Into Clinical Practice
Tanya Dorff, MD, City of Hope Comprehensive Cancer Center, explains the challenges of providing useful and accurate prognostic information to patients with mCRPC, how the prognostic model from the CALGB 90401 trial may alleviate some of those issues, and what needs to happen to move the model into standard practice. Her comments are in relation to her recent editorial in the Journal of Clinical Oncology, “Incorporating Prognostic Models Into Clinical Practice for Patients With Castration-Resistant Prostate Cancer.” ...
Advertisement
Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Zachary BessetteASCO 2023 | May 26, 2023
PSA nadir ≥0.1 ng/mL within 6 months of RT completion may be prognostic for long-term outcomes in patients receiving ...
Read More
Zachary BessetteASCO 2023 | May 26, 2023
A prospective study shows activity after treatment intensification with a triplet combination regimen in patients with RCCvh.
Zachary BessetteASCO 2023 | May 26, 2023
The largest analysis of outcomes for patients with sarcomatoid or rhabdoid metastatic nccRCC treated with IO-based regimens.
Zachary BessetteASCO 2023 | May 26, 2023
Post hoc analyses from JAVELN Bladder 100 shed light on the long-term safety profile of avelumab first-line maintenance.

Video Insights

Clinical discussions with experts in the field